...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: 6%
Reply New Message
Back To Forum List View
6%
2
KayakerBC
Dec 14, 2022 02:52PM
Re: 6%
3
fuzzyjr
Dec 14, 2022 03:46PM
Re: 6%

KayakerBC
Dec 15, 2022 10:11AM
Re: 6%
3
fuzzyjr
Dec 15, 2022 10:27AM
Re: 6%

KayakerBC
Dec 15, 2022 10:39AM
Re: 6%
2
KOO-KOO2
Dec 15, 2022 10:55AM
Re: 6%
2
fuzzyjr
Dec 15, 2022 11:10AM

If management goes with the royalty revenue stream option, all monies go to ZCC.

If management goes with the sale of the ZEN-3694 option, all monies go to ZCC.

No monies go to RVX. RVX is a separate company.

 

Koo

1 Recommendations
Re: 6%
1
fuzzyjr
Dec 15, 2022 11:28AM
Re: 6%
1
fuzzyjr
Dec 15, 2022 11:29AM
Re: 6%
1
KOO-KOO2
Dec 15, 2022 11:36AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply